Latest Administration News

Terra Metals reports robust drilling results from its Dante Project, revealing high-grade titanium alongside copper, PGMs, and vanadium, while securing an option to expand its tenement holdings.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

Lincoln Minerals reports compelling Pre-Feasibility Study results for its Kookaburra Graphite Project, alongside strategic cost reductions and exploration progress in uranium and base metals on South Australia's Eyre Peninsula.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

Winchester Energy Limited reported steady production levels alongside ongoing cost reduction efforts in its December 2024 quarterly report, highlighting operational resilience despite currency headwinds.

Norfolk Metals reports progress in its Orroroo Uranium and Roger River projects, unveiling new exploration targets and maintaining a solid financial footing with $2.66 million in cash.

Nova Eye Medical Limited is raising A$6.6 million to strengthen its financial position following resolved supply chain disruptions, while reporting strong sales growth and nearing profitability in its glaucoma division.

Geopacific Resources reported a challenging quarter ending December 2024 with significant cash outflows, prompting a $40 million entitlement offer to secure funding for its Woodlark Project.

Allup Limited reports a challenging quarter with significant cash outflows from operations and investing, relying heavily on financing activities. The company is pursuing a $1.3 million entitlement issue to support ongoing feasibility work.

Northern Minerals Limited reported a $7.56 million net cash outflow from operating activities in the December 2024 quarter, offset by $28.5 million raised through borrowings, leaving a healthy cash balance of $35.76 million.

Prescient Therapeutics has secured FDA clearance to initiate its Phase 2 PTX-100 trial for relapsed cutaneous T-cell lymphoma, alongside progress in its cell therapy platforms and a solid cash position bolstered by a recent R&D rebate.

Titanium Sands Limited has made significant progress in securing its Industrial Mining License for the Mannar Project in Sri Lanka, while preparing for a crucial funding placement to support ongoing development.